Literature DB >> 15184254

Using nuclear morphometry to discriminate the tumorigenic potential of cells: a comparison of statistical methods.

Pamela Wolfe1, James Murphy, John McGinley, Zongjian Zhu, Weiqin Jiang, E Brigitte Gottschall, Henry J Thompson.   

Abstract

Despite interest in the use of nuclear morphometry for cancer diagnosis and prognosis as well as to monitor changes in cancer risk, no generally accepted statistical method has emerged for the analysis of these data. To evaluate different statistical approaches, Feulgen-stained nuclei from a human lung epithelial cell line, BEAS-2B, and a human lung adenocarcinoma (non-small cell) cancer cell line, NCI-H522, were subjected to morphometric analysis using a CAS-200 imaging system. The morphometric characteristics of these two cell lines differed significantly. Therefore, we proceeded to address the question of which statistical approach was most effective in classifying individual cells into the cell lines from which they were derived. The statistical techniques evaluated ranged from simple, traditional, parametric approaches to newer machine learning techniques. The multivariate techniques were compared based on a systematic cross-validation approach using 10 fixed partitions of the data to compute the misclassification rate for each method. For comparisons across cell lines at the level of each morphometric feature, we found little to distinguish nonparametric from parametric approaches. Among the linear models applied, logistic regression had the highest percentage of correct classifications; among the nonlinear and nonparametric methods applied, the Classification and Regression Trees model provided the highest percentage of correct classifications. Classification and Regression Trees has appealing characteristics: there are no assumptions about the distribution of the variables to be used, there is no need to specify which interactions to test, and there is no difficulty in handling complex, high-dimensional data sets containing mixed data types.

Entities:  

Mesh:

Year:  2004        PMID: 15184254

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  6 in total

1.  Penalized Fisher Discriminant Analysis and Its Application to Image-Based Morphometry.

Authors:  Wei Wang; Yilin Mo; John A Ozolek; Gustavo K Rohde
Journal:  Pattern Recognit Lett       Date:  2011-11-01       Impact factor: 3.756

2.  Morphometric sum optical density as a surrogate marker for ploidy status in prostate cancer: an analysis in 180 biopsies using logistic regression and binary recursive partitioning.

Authors:  Girish Venkataraman; Vijayalakshmi Ananthanarayanan; Gladell P Paner; Rui He; Saeedeh Masoom; James Sinacore; Robert C Flanigan; Eva M Wojcik
Journal:  Virchows Arch       Date:  2006-08-03       Impact factor: 4.064

3.  Computational image analysis of nuclear morphology associated with various nuclear-specific aging disorders.

Authors:  Siwon Choi; Wei Wang; Alexandrew J S Ribeiro; Agnieszka Kalinowski; Siobhan Q Gregg; Patricia L Opresko; Laura J Niedernhofer; Gustavo K Rohde; Kris Noel Dahl
Journal:  Nucleus       Date:  2011-11-01       Impact factor: 4.197

4.  Machine Learning for Nuclear Mechano-Morphometric Biomarkers in Cancer Diagnosis.

Authors:  Adityanarayanan Radhakrishnan; Karthik Damodaran; Ali C Soylemezoglu; Caroline Uhler; G V Shivashankar
Journal:  Sci Rep       Date:  2017-12-20       Impact factor: 4.379

5.  Analyzing huge pathology images with open source software.

Authors:  Christophe Deroulers; David Ameisen; Mathilde Badoual; Chloé Gerin; Alexandre Granier; Marc Lartaud
Journal:  Diagn Pathol       Date:  2013-06-06       Impact factor: 2.644

6.  Development of a nuclear morphometric signature for prostate cancer risk in negative biopsies.

Authors:  Peter H Gann; Ryan Deaton; Anup Amatya; Mahesh Mohnani; Erika Enk Rueter; Yirong Yang; Viju Ananthanarayanan
Journal:  PLoS One       Date:  2013-07-26       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.